New progress in oral SERD: Sanofi and Eli Lilly announce test results

Endocrine therapy (ET) is the main treatment option for ER+ (estrogen receptor positive)/HER2- (HER2 negative) breast cancer patients

Recently, Sanofi’s SAR439859 and Eli Lilly’s LY3484356 have successively announced the results of recent clinical trials, injecting new vitality into the SERD track

First, let's understand what is SERD?

SERD is a kind of small molecule.

Sanofi SAR439859 (Amcenestrant)

SAR439859 is an oral SERD developed by Sanofi

In the AMEERA-1 phase study of pretreated patients with ER+/HER2- advanced breast cancer, once a day (QD) 150-600mg SAR439859 showed an average ER occupancy rate of 94%, plasma concentration> 100 ng/mL and good safety

A prospective, randomized, double-blind phase III study of AMEERA-5 is currently underway to compare SAR439859+pebecili with letrozole+pebecili in patients with advanced, locally recurring, or metastatic ER+/HER2- breast cancer The efficacy and safety

Eli Lilly LY3484356

LY3484356 is an oral SERD developed by Eli Lilly.

As of November 9, 2020, 28 patients have been enrolled (n=24 for breast cancer, n=4 for endometrial cancer), with a dose of 200-1200 mgQD

Treatment of emergent adverse events (TEAEs) are mainly grade 1-2, including nausea (32%), fatigue (25%), and diarrhea (18%)

Oral SERD track players

(Source: ClinicalTrials.

The current global SERD targeted drug market is mainly based on the sales scale of fulvestrant, which has grown from 700 million U.

Reference source:

1.

2.